Shares of Fulgent Genetics (NASDAQ: FLGT) have been hovering near their all-time high after a big jump this summer. After rising around 231% year to date, can this coronavirus stock put up additional big gains for investors?
The relatively young diagnostics company owes its recent success to its quick development of coronavirus tests, including an at-home service the FDA authorized in June. Fulgent's Picture Genetics business is selling so many at-home sample-collection kits that the company expects at least $300 million in total revenue this year.
Image source: Getty Images.
For further details see:
Fulgent Genetics Stock: Buy at the High?